Search Result

Results for "

demethylases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Demethylase (94) Antibiotic (3) Apoptosis (18) Autophagy (4) Bacterial (5) CFTR (2) CMV (1) Cytochrome P450 (7) DNA/RNA Synthesis (2) Dopamine Receptor (2) Endogenous Metabolite (8) Estrogen Receptor/ERR (1) Fat Mass and Obesity-associated Protein (FTO) (3) Fungal (14) HDAC (5) Hedgehog (3) Histone Methyltransferase (2) HSV (1) MDM-2/p53 (1) Mitochondrial Metabolism (4) MMP (1) Monoamine Oxidase (9) TNF Receptor (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (104) Cardiovascular Disease (4) Infection (16) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (6)

By Targets:

Histone Demethylase (94)

Antibiotic (3)

Apoptosis (18)

Autophagy (4)

Bacterial (5)

CFTR (2)

CMV (1)

Cytochrome P450 (7)

DNA/RNA Synthesis (2)

Dopamine Receptor (2)

Endogenous Metabolite (8)

Estrogen Receptor/ERR (1)

Fat Mass and Obesity-associated Protein (FTO) (3)

Fungal (14)

HDAC (5)

Hedgehog (3)

Histone Methyltransferase (2)

HSV (1)

MDM-2/p53 (1)

Mitochondrial Metabolism (4)

MMP (1)

Monoamine Oxidase (9)

TNF Receptor (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (104)

Cardiovascular Disease (4)

Infection (16)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (6)

137

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Histone Demethylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137187

FB23	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FB23 is a potent and selective FTO demethylase inhibitor with an IC₅₀ of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N ⁶-methyladenosine (m6A) demethylase activity .

HY-116034

Arasertaconazole	Cytochrome P450 Bacterial Fungal	Infection
Arasertaconazole is a potent 14α-lanosterol demethylase inhibitor. Arasertaconazole has antifungal and antibacterial activity .

HY-122746

E67-2	Histone Methyltransferase	Cancer
E67-2, as the E67 derivative, is a low-toxicity, selective KIAA1718 Jumonji domain inhibitor with an IC₅₀ value of 3.4 µM. E67-2 selectively inhibits histone H3 lysine 9 (H3K9) Jumonji demethylase as well as histone H3 lysine 4 (H3K4) demethylase .

HY-160183

LSD1-IN-29

Histone Demethylase Cancer

LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

LSD1-IN-29	Histone Demethylase	Cancer
LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of *lysine-specific demethylase* 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i** values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

HY-141677

INCB059872	Histone Demethylase	Cancer
INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia .

HY-141677A

INCB059872 dihydrochloride	Histone Demethylase	Cancer
INCB059872 dihydrochloride is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 dihydrochloride can be used for the research of myeloid leukemia .

HY-115747

Namoline	Histone Demethylase	Cancer
Namoline, a γ-pyrone, is a selective and reversible *Lysine-specific demethylase* 1 (LSD1)** inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research .

HY-13643

Daminozide 2 Publications Verification	Histone Demethylase	Cancer
Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested .

HY-N2560

Senecionine Senecionan-11,16-dione, 12-hydroxy-; Aureine; Senecionin	Others	Metabolic Disease
Senecionine (Senecionan-11,16-dione, 12-hydroxy-) is a pyrrolizidine alkaloid could be isolated from Senecio vulgaris. Senecionine decreases the activities of glutathione S-transferase, aminopyrine demethylase and arylhydrocarbon hydroxylase (AHH) .

HY-117426

MO-I-500	Others	Cancer
MO-I-500 is a pharmacological of FTO inhibitor with an IC₅₀ of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer .

HY-139348

PFI-90	Histone Demethylase Apoptosis	Cancer
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).

HY-151106

FTO-IN-8	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC₅₀ value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity .

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-147697

LSD1-IN-21	Histone Demethylase TNF Receptor	Inflammation/Immunology Cancer
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity .

HY-W017132

2,4-PDCA	Histone Demethylase	Cancer
2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including *JmjC domain-containing family of histone demethylases* (JHDMs)**. 2,4-PDCA is a target chemical in the field of bio-based plastics .

HY-15648F

GSK-J4 hydrochloride Maximum Cited Publications 34 Publications Verification	Histone Demethylase	Cancer
GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 .

HY-127103

FB23-2 5+ Cited Publications	Apoptosis	Cancer
FB23-2 is a potent and selective inhibitor of mRNA N ⁶-methyladenosine (m ⁶A) demethylase FTO, with an IC₅₀ of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-146670

KDM5B-IN-3	Histone Demethylase	Cancer
KDM5B-IN-3 (Compound 5) is a histone lysine specific demethylase 5B (KDM5B/JARID1B) inhibitor with an IC₅₀ of 9.32 μM. KDM5B-IN-3 can be used for the research of gastric cancer .

HY-15648B

GSK-J4 Maximum Cited Publications 34 Publications Verification	Histone Demethylase Apoptosis	Cancer
GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 . GSK-J4 induces endoplasmic reticulum stress-related apoptosis .

HY-152032

LSD1-IN-23	Histone Demethylase	Cancer
LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of *lysine specific demethylase* 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC₅₀** value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) .

HY-109169

Bomedemstat IMG-7289	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-109169B

Bomedemstat hydrochloride IMG-7289 hydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-109169C

Bomedemstat dihydrochloride IMG-7289 dihydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) dihydrochloride is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat dihydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat dihydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-B0735A

Fenoldopam mesylate 4 Publications Verification Fenoldopam methanesulfonate; SKF-82526 mesylate	Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam mesylate (SKF-82526) is a D₁ receptor agonist and a novel *lysine-specific demethylase* 1 (LSD1) inhibitor (IC₅₀**=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-109169A

Bomedemstat ditosylate IMG-7289 ditosylate	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-131970

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of *lysine specific demethylase* 1(LSD1)/Histone deacetylase 6 (HDAC6)**, with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) .

HY-147777

*14α-Demethylase/DNA Gyrase-IN-2*	Bacterial DNA/RNA Synthesis	Infection
14α-Demethylase/DNA Gyrase-IN-2 (Compound 6a) is a potent inhibitor of *14α-Demethylase/DNA* Gyrase. 14α-Demethylase/DNA Gyrase-IN-2 has antimicrobial activities .

HY-147778

*14α-Demethylase/DNA Gyrase-IN-1*	Bacterial DNA/RNA Synthesis	Infection
14α-Demethylase/DNA Gyrase-IN-1 (Compound 7c) is a potent inhibitor of *14α-Demethylase/DNA* Gyrase. 14α-Demethylase/DNA Gyrase-IN-1 has antimicrobial activities .

HY-156405

FTO-IN-10	Fat Mass and Obesity-associated Protein (FTO) Autophagy	Metabolic Disease
FTO-IN-10 (compound 7) is a potent human demethylase FTO (the fat mass and obesity-associated protein) inhibitor with an IC₅₀ of 4.5 μM. FTO-IN-10 enters the FTO’s structural domain II binding pocket through hydrophobic and hydrogen bonding interactions. FTO-IN-10 induces DNA damage and autophagic cell death in A549 cells .

HY-112308

NCGC00247743

1 Publications Verification

Histone Demethylase Cancer

NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

NCGC00247743 1 Publications Verification	Histone Demethylase	Cancer
NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

HY-122635A

T-448	Histone Demethylase	Neurological Disease
T-448 is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀ of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons .

HY-15774A

CBB1003 hydrochloride

Histone Demethylase Cancer

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
HY-15774

CBB1003

Histone Demethylase Cancer

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003 hydrochloride	Histone Demethylase	Cancer
CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003	Histone Demethylase	Cancer
CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

HY-122635

T-448 free base	Histone Demethylase	Neurological Disease
T-448 free base is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀ of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons .

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent *lysine-specific demethylase* 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis** in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice .

HY-12635

SP2509

5+ Cited Publications

Histone Demethylase Apoptosis Cancer

SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC₅₀ of 13 nM .
HY-15648

GSK-J1

5+ Cited Publications

Histone Demethylase Cancer

GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC₅₀ of 60 nM towards KDM6B.

SP2509 5+ Cited Publications	Histone Demethylase Apoptosis	Cancer
SP2509 is a potent and selective antagonist of *lysine specific demethylase* 1 (LSD1) with an IC₅₀** of 13 nM .

GSK-J1 5+ Cited Publications	Histone Demethylase	Cancer
GSK-J1 is a potent inhibitor of *H3K27me3/me2-demethylases* JMJD3/KDM6B and UTX/KDM6A, with IC₅₀** of 60 nM towards KDM6B.

HY-103085

T-3775440 hydrochloride 2 Publications Verification	Histone Demethylase	Cancer
T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase (LSD1) inhibitor with an IC₅₀ value of 2.1 nM.

HY-117226A

GSK 690 Hydrochloride 1 Publications Verification	Histone Demethylase	Others
GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-117226

GSK 690

Histone Demethylase Cancer

GSK 690 is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

GSK 690	Histone Demethylase	Cancer
GSK 690 is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-108706

KDM2A/7A-IN-1	Histone Demethylase	Cancer
KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of *histone lysine demethylases* KDM2A/7A, with an IC₅₀** of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases .

HY-15648D

GSK-J1 lithium salt

Histone Demethylase Cancer

GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC₅₀ of 60 nM towards KDM6B.

GSK-J1 lithium salt	Histone Demethylase	Cancer
GSK-J1 lithium salt is a potent inhibitor of *H3K27me3/me2-demethylases* JMJD3/KDM6B and UTX/KDM6A, with IC₅₀** of 60 nM towards KDM6B.

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent *lysine-specific demethylase* 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis** in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells .

HY-100546A

GSK-LSD1 dihydrochloride 5 Publications Verification	Histone Demethylase Monoamine Oxidase	Cancer
GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.

HY-15648G

GSK-J1 sodium

Histone Demethylase Cancer

GSK-J1 sodium is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC₅₀ value of 60 nM towards KDM6B .

HY-148807

Zavondemstat QC8222 free base; TACH 101 free base	Histone Demethylase	Cancer
Zavondemstat (QC8222; TACH 101) is an inhibitor of *histone lysine demethylase* 4D (KDM4D**) with antineoplastic activity .

HY-12725

ML324 5+ Cited Publications	Histone Demethylase HSV CMV	Cancer
ML324 is a potent JMJD2 demethylase inhibitor with antiviral activity. ML324 also exhibits inhibition for the histone demethylase KDM4B, with an IC₅₀ of 4.9 μM. ML324 has potent anti-viral activity against both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression .

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of *lysine specific demethylase-1 (LSD1)* with an IC₅₀ of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

Cat. No.	Product Name	Target	Research Area

HY-P2509

Histone H2A (1-20)

Peptides Others

Histone H2A (1-20), a 35-residue a peptide of histone H2A, is a substrate for methyltransferase/demethylase enzymes .

HY-P1108A

Astressin 2B TFA	CFTR	Others
Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC₅₀ values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .

HY-P4756

*N-(2-Carbamoyl-ethyl)-Val-Leu-anilide*	Peptides	Others
N-(2-Carbamoyl-ethyl)-Val-Leu-anilide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P1108

Astressin 2B	CFTR	Others
Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC₅₀ values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .

HY-P2592

Ro 23-7014

Peptides Others

Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .

HY-P2252

H3K27(Me) (15-34)	Peptides	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P4521

*Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt*	MMP	Others
Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt is a MMP12 substrate, and can be used to detect MMP12 enzyme activity .

HY-P3066

SKF 100398 d(CH2)5Tyr(Et)VAVP	Vasopressin Receptor	Metabolic Disease
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13643

Daminozide 2 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Disease Research Fields Biological Pesticide Research Cancer Agricultural Research	Histone Demethylase
Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested .

HY-N2560

Senecionine Senecionan-11,16-dione, 12-hydroxy-; Aureine; Senecionin	Pterogyne nitens Tul. Alkaloids Pyrrole Alkaloids Classification of Application Fields Erinacea anthyllis Link Source classification Metabolic Disease Plants Compositae Disease Research Fields	Others
Senecionine (Senecionan-11,16-dione, 12-hydroxy-) is a pyrrolizidine alkaloid could be isolated from Senecio vulgaris. Senecionine decreases the activities of glutathione S-transferase, aminopyrine demethylase and arylhydrocarbon hydroxylase (AHH) .

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Structural Classification Microorganisms Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-N10340

Clausine E Clauszoline I	Structural Classification Alkaloids Classification of Application Fields Source classification Rutaceae Plants Disease Research Fields Clausena harmandiana (Pierre) Guillaumin Cancer	Others
Clausine E, is a alkaloid which can be isolated from Clausena excavata, is a inhibitor of fat mass and obesity-associated protein (FTO) demethylase. Clausine E shows inhibitory activities against proliferation of synoviocytes and cancer cells.

HY-113038B

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Structural Classification Immune System Disorder Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields Cancer	Histone Demethylase Endogenous Metabolite
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases .

HY-113038A

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Histone Demethylase Endogenous Metabolite
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases .

HY-113039R

L-2-Hydroxyglutaric acid (Standard) (S)-2-Hydroxyglutaric acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid (Standard) is the analytical standard of L-2-Hydroxyglutaric acid. This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W015114R

L-2-Hydroxyglutaric acid disodium (Standard) (S)-2-Hydroxyglutaric acid disodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of L-2-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

Cat. No.	Product Name	Chemical Structure

HY-17514S

Itraconazole-d5

Itraconazole-d₅ is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects[1][2][3].

HY-113038AS

α-Hydroxyglutaric acid-13C5 disodium

α-Hydroxyglutaric acid- ¹³C₅ (sodium) is the ¹³C labeled α-Hydroxyglutaric acid sodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) sodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid sodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-17447SA

Tranylcypromine-d5 hydrochloride

Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

HY-113038AS1

α-Hydroxyglutaric acid-d4 disodium

α-Hydroxyglutaric acid-d₄ (disodium) is the deuterium labeled α-Hydroxyglutaric acid disodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-17514S2

Itraconazole-d9

Itraconazole-d₉ is the deuterium labeled Itraconazole[1]. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[2][3][4][5].

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks